Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
XORTX Therapeutics Inc
XRTX
Primary Symbol:
V.XRTX
Healthcare
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance...
its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSXV:XRTX)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(173)
•••
Peggy123
X
View Profile
View Bullboard History
Comment by
Peggy123
on Sep 25, 2023 6:16pm
RE:RE:Xirtex was $10++ after Rollback @ 11 :1
been 8 weeks lol papi
(2066)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Jul 28, 2023 7:29pm
RE:Xirtex was $10++ after Rollback @ 11 :1
Years away from commercialization and more funding required
Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study
posted Jun 13, 2024 9:00am by
Revive Therapeutics Ltd.
-
|
“We are pleased with the FDA’s recommendations for our proposed clinical study, which provides a pathway for the clinical development of Bucillamine as a potential treatment for Long COVID,” said Michael Frank, CEO of Revive. “We aim to finalize the clinical study protocol and submit a new IND, which will cross reference our current IND to obtain FDA approval to proceed with the clinical trial for Long COVID.” ...read more
(173)
•••
Peggy123
X
View Profile
View Bullboard History
Comment by
Peggy123
on Jul 28, 2023 7:07pm
RE:RE:Xirtex was $10++ after Rollback @ 11 :1
WTF happened today What a joke Papi
(23)
•••
Moonrunner
X
View Profile
View Bullboard History
Comment by
Moonrunner
on Jul 27, 2023 10:23am
RE:Xirtex was $10++ after Rollback @ 11 :1
It has been a rough ride no doubt, give it a few more weeks.
(0)
•••
Stockloss
X
View Profile
View Bullboard History
Post by
Stockloss
on Jul 26, 2023 11:02pm
Xirtex was $10++ after Rollback @ 11 :1
Very frustrating to see a $10 ++ Rollback has lost 90%. Back to $1.00, the original price. I've lost $17K after Holding 100K at 25c. I don't know how many other people are
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on May 04, 2023 7:00am
New Press Release - FDA Confirms Eligibility of XORLO(TM) for Accelerated Approval
XORTX Expands Options for Accelerated Approval CALGARY, Alberta, May 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Apr 21, 2023 7:00am
New Press Release - XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease
CALGARY, Alberta, April 21, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce...
read article.
(2)
•••
KOkidneydisease
X
View Profile
View Bullboard History
Comment by
KOkidneydisease
on Apr 11, 2023 2:31pm
RE:RE:XORTX - $2 in 2 weeks.
Not sure what you mean. perhaps you can add context? Grow up? Papi? The bid/ask can change, absolutely, but the underlying fundamentals are still the same and it seems others are taking note. and
...more
(173)
•••
Peggy123
X
View Profile
View Bullboard History
Comment by
Peggy123
on Apr 10, 2023 5:44pm
RE:XORTX - $2 in 2 weeks.
That changes in a nano second Grow up Papi
(2)
•••
KOkidneydisease
X
View Profile
View Bullboard History
Post by
KOkidneydisease
on Apr 06, 2023 4:43pm
XORTX - $2 in 2 weeks.
The meeting with the FDA on May 1 is coming fast. XORTX also has to get the share price above $1 for the NASDAQ by mid May Partner conversations Phase 3 trials Positive Top Line
...more
(2)
•••
KOkidneydisease
X
View Profile
View Bullboard History
Post by
KOkidneydisease
on Apr 05, 2023 5:36pm
also, are there any recent analysts reports available?
might be a good time for some?
(2)
•••
KOkidneydisease
X
View Profile
View Bullboard History
Post by
KOkidneydisease
on Apr 05, 2023 5:33pm
XORTX is on the move for good reason.
I've been a long term holder in this stock because I like the story. I don't like the direction of the stock movement but thats what happens when the majority of the holders are funds that buy
...more
(2)
•••
KOkidneydisease
X
View Profile
View Bullboard History
Comment by
KOkidneydisease
on Apr 05, 2023 5:04pm
RE:Keep an eye on XRTX this week ;)
Funny. Who advertises they are 'going to' load the boat? They advertise they just did! I have picked up all I can in my 'spec' holdings. The company meets the FDA in May.
(77)
•••
Investorpigs
X
View Profile
View Bullboard History
Comment by
Investorpigs
on Apr 03, 2023 2:38pm
RE:RE:Keep an eye on XRTX this week ;)
That's expected with these type of companies. So trading at 40% under cash on hand plus giving 0 value to the 19M invested last year. Low float, will fly shortly. Just watch.
(2066)
•••
lscfa
X
View Profile
View Bullboard History
Comment by
lscfa
on Apr 02, 2023 3:47pm
RE:Keep an eye on XRTX this week ;)
Burned through $14 million of cash last year. So only 1 year of cash left.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Xcyte Digital Corp. Announces Execution of Definitive Agreement with MCON Live Inc.
Flow Rate and Helium Concentration Confirms Topaz Project as World-Class Helium Well
AirBoss of America Corp. Class Action Certification and Settlement
The Convenience of Modern Banking With the Benefits of Bitcoin Has Arrived
A Junior Copper-Gold Stock Trading at a Bargain of Monumental Proportions